Pulmonary complications of inflammatory myopathy.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pulmonary manifestations contribute significantly to the morbidity and mortality of the idiopathic inflammatory myopathies, ranging from intrinsic lung disease to secondary complications that include aspiration pneumonia, opportunistic infection, congestive heart failure, and hypoventilation. Newer classification schemes for interstitial lung disease have permitted closer correlation between histologic subtype and clinical outcome, while diagnostic techniques such as bronchoalveolar lavage have begun to define the cellular elements responsible for immune-mediated pulmonary dysfunction. Investigators have identified several serum markers correlating with inflammatory disease activity in the lung that should enhance noninvasive monitoring of therapeutic responses to newer regimens involving agents such as cyclosporine and tacrolimus. Taken together, these advances have contributed to better understanding of the immunopathogenesis of myositis-associated interstitial lung disease that should ultimately translate into more effective treatment.

Original languageEnglish
Pages (from-to)409-414
Number of pages6
JournalCurrent Rheumatology Reports
Volume4
Issue number5
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Myositis
Interstitial Lung Diseases
Lung
Aspiration Pneumonia
Hypoventilation
Opportunistic Infections
Tacrolimus
Bronchoalveolar Lavage
Cyclosporine
Lung Diseases
Heart Failure
Biomarkers
Research Personnel
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Pulmonary complications of inflammatory myopathy. / Ascherman, Dana.

In: Current Rheumatology Reports, Vol. 4, No. 5, 01.10.2002, p. 409-414.

Research output: Contribution to journalArticle

@article{9056b223eed9476689ca4f9e31c1fe77,
title = "Pulmonary complications of inflammatory myopathy.",
abstract = "Pulmonary manifestations contribute significantly to the morbidity and mortality of the idiopathic inflammatory myopathies, ranging from intrinsic lung disease to secondary complications that include aspiration pneumonia, opportunistic infection, congestive heart failure, and hypoventilation. Newer classification schemes for interstitial lung disease have permitted closer correlation between histologic subtype and clinical outcome, while diagnostic techniques such as bronchoalveolar lavage have begun to define the cellular elements responsible for immune-mediated pulmonary dysfunction. Investigators have identified several serum markers correlating with inflammatory disease activity in the lung that should enhance noninvasive monitoring of therapeutic responses to newer regimens involving agents such as cyclosporine and tacrolimus. Taken together, these advances have contributed to better understanding of the immunopathogenesis of myositis-associated interstitial lung disease that should ultimately translate into more effective treatment.",
author = "Dana Ascherman",
year = "2002",
month = "10",
day = "1",
language = "English",
volume = "4",
pages = "409--414",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Pulmonary complications of inflammatory myopathy.

AU - Ascherman, Dana

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Pulmonary manifestations contribute significantly to the morbidity and mortality of the idiopathic inflammatory myopathies, ranging from intrinsic lung disease to secondary complications that include aspiration pneumonia, opportunistic infection, congestive heart failure, and hypoventilation. Newer classification schemes for interstitial lung disease have permitted closer correlation between histologic subtype and clinical outcome, while diagnostic techniques such as bronchoalveolar lavage have begun to define the cellular elements responsible for immune-mediated pulmonary dysfunction. Investigators have identified several serum markers correlating with inflammatory disease activity in the lung that should enhance noninvasive monitoring of therapeutic responses to newer regimens involving agents such as cyclosporine and tacrolimus. Taken together, these advances have contributed to better understanding of the immunopathogenesis of myositis-associated interstitial lung disease that should ultimately translate into more effective treatment.

AB - Pulmonary manifestations contribute significantly to the morbidity and mortality of the idiopathic inflammatory myopathies, ranging from intrinsic lung disease to secondary complications that include aspiration pneumonia, opportunistic infection, congestive heart failure, and hypoventilation. Newer classification schemes for interstitial lung disease have permitted closer correlation between histologic subtype and clinical outcome, while diagnostic techniques such as bronchoalveolar lavage have begun to define the cellular elements responsible for immune-mediated pulmonary dysfunction. Investigators have identified several serum markers correlating with inflammatory disease activity in the lung that should enhance noninvasive monitoring of therapeutic responses to newer regimens involving agents such as cyclosporine and tacrolimus. Taken together, these advances have contributed to better understanding of the immunopathogenesis of myositis-associated interstitial lung disease that should ultimately translate into more effective treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036777859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036777859&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 409

EP - 414

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 5

ER -